Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has entered into a drug discovery collaboration agreement with PeptiDream Inc., (Kanagawa, Japan; President and CEO: Patrick C. Reid, “PeptiDream”), to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono’s interest.

 Under the terms of the agreement, PeptiDream will identify and optimize macrocyclic constrained peptide drug candidates for multiple targets of interest selected by Ono, by using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Ono will obtain the exclusive worldwide rights to develop and commercialize such drug candidates. Ono will pay to PeptiDream an up-front payment, research funding, and success-based milestone payments on research, development and commercialization, as well as tiered royalties based on global net sales.

 “We appreciate PeptiDream's automated PDPS platform technology and are pleased to collaborate with PeptiDream in the discovery of novel macrocyclic constrained peptide drugs,” said Toichi Takino, Senior Executive Officer/ Executive Director, Discovery and Research of Ono. “We believe that this new collaboration will accelerate our peptide drug discovery efforts and bring innovative drugs for patients.”

 “We are excited to announce this collaboration with ONO following our non-exclusive Technology License Agreement in March 2021,” said Keiichi Masuya, Ph.D., Chief Operating Officer of PeptiDream. “ We believe that through this research collaboration in parallel with the drug discovery research using PDPS which is already in operation at ONO, we will accelerate drug discovery research efforts on several new targets and enable deeper collaboration involving the application of PDPS between the two companies.”

 Ono entered into non-exclusive license agreement with PeptiDream on automated PDPS platform technology in March 2021. With this new collaboration, we will be committed to identifying and developing macrocyclic constrained peptide drugs with high binding affinity to drug discovery targets with PeptiDream by using PDPS platform technology, and bringing innovative drugs for patients suffering from certain diseases as quickly as possible.

About PeptiDream Inc.

 PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology, a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate (PDC), and multi-functional peptide conjugates (MPC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of discovery and development partners driving the development and commercialization of a broad and diversified pipeline of investigational therapeutics. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma. PeptiDream is headquartered in Kawasaki, Japan. For more information about PeptiDream, its science and pipeline, please visit www.peptidream.com .

Source:- Ono